vimarsana.com

Latest Breaking News On - Endocrinology rare disease - Page 1 : vimarsana.com

Ascendis Pharma Reports First Quarter 2024 Financial Results

Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercia.

United kingdomUnited statesGreat britainTim leeJan mikkelsenMelinda bakerAscendis pharmaPatti bankAmerican society for clinical oncologyExchange commissionChief executiveEndocrinology rare diseaseMetabolic diseasesEuropean economic areaBiologics license applicationPrescription drug user fee act

Ascendis Pharma A/S : Form 6-K - MarketScreener

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K .

New zealandUnited kingdomUnited statesRepublic ofUnited arab emiratesRedwood cityHong kongSaudi arabiaRepublic of chinaTaiwan generalGreat britainSandoz gmbAscendis pharmaMichael wolff jensenBiopartners gmbEli lilly

Ascendis Pharma Reports First Quarter 2024 Financial Results

— Rollout of YORVIPATH®initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31

United kingdomUnited statesGreat britainAscendis pharmaJan mikkelsenExchange commissionAmerican society for clinical oncologyChief executiveEndocrinology rare diseaseMetabolic diseasesEuropean economic areaBiologics license applicationPrescription drug user fee actNew drug applicationBelieve trialAmerican society

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesTim leeMelinda bakerJan mikkelsenAscendis pharmaStefan klotterEyconis incPatti bankExchange commissionChief executiveEurope directInternational marketsEndocrinology rare diseaseBiologics license applicationPrescription drug user fee actNew drug application

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024TransCon CNP pivotal App.

United statesAscendis pharmaMelinda bakerTim leeJan mikkelsenEyconis incPatti bankExchange commissionChief executiveEurope directInternational marketsEndocrinology rare diseaseBiologics license applicationPrescription drug user fee actNew drug applicationInvestigational new drug

vimarsana © 2020. All Rights Reserved.